VNDA VANDA PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended June 30, 2026, VANDA PHARMACEUTICALS INC reported revenue of $50.5M (down 3.9% from a year earlier), net income of −$62.5M and diluted EPS of −$1.04; over the last four quarters revenue was $216M and net income −$275M; for the fiscal year ended December 2025 revenue was $216M, up 8.7% on the year before.
VNDA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $216M, gross profit n/a, operating income −$151M, net income −$221M (margin -102.0%), EPS −$3.74
- Fiscal year ended Dec 2024: revenue $199M, gross profit n/a, operating income −$40.7M, net income −$18.9M (margin -9.5%), EPS −$0.33
- Fiscal year ended Dec 2023: revenue $193M, gross profit n/a, operating income −$14.0M, net income $2.50M (margin 1.3%), EPS $0.04
- Fiscal year ended Dec 2022: revenue $254M, gross profit n/a, operating income $6.33M, net income $6.30M (margin 2.5%), EPS $0.11
- Fiscal year ended Dec 2021: revenue $269M, gross profit n/a, operating income $42.2M, net income $33.2M (margin 12.4%), EPS $0.58
VNDA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $50.5M (down 3.9% year over year), net income −$62.5M, EPS −$1.04
- Quarter ended Mar 31, 2026: revenue $51.7M (up 3.4% year over year), net income −$48.6M, EPS −$0.82
- Quarter ended Dec 31, 2025 (from the annual report): revenue $57.2M (up 7.6% year over year), net income −$141M, EPS −$2.40
- Quarter ended Sep 30, 2025: revenue $56.3M (up 18.1% year over year), net income −$22.6M, EPS −$0.38
- Quarter ended Jun 30, 2025: revenue $52.6M (up 4.2% year over year), net income −$27.2M, EPS −$0.46
- Quarter ended Mar 31, 2025: revenue $50.0M (up 5.4% year over year), net income −$29.5M, EPS −$0.50
- Quarter ended Dec 31, 2024 (from the annual report): revenue $53.2M (up 17.5% year over year), net income −$4.91M, EPS −$0.09
- Quarter ended Sep 30, 2024: revenue $47.7M (up 22.8% year over year), net income −$5.32M, EPS −$0.09
- Quarter ended Jun 30, 2024: revenue $50.5M (up 9.6% year over year), net income −$4.52M, EPS −$0.08
- Quarter ended Mar 31, 2024: revenue $47.5M (down 24.1% year over year), net income −$4.15M, EPS −$0.07
- Quarter ended Dec 31, 2023 (from the annual report): revenue $45.3M (down 29.8% year over year), net income −$2.41M, EPS −$0.05
- Quarter ended Sep 30, 2023: revenue $38.8M (down 40.6% year over year), net income $137K, EPS $0.00
- Quarter ended Jun 30, 2023: revenue $46.1M (down 28.5% year over year), net income $1.52M, EPS $0.03
- Quarter ended Mar 31, 2023: revenue $62.5M (up 3.8% year over year), net income $3.25M, EPS $0.06
- Quarter ended Dec 31, 2022 (from the annual report): revenue $64.5M (down 5.2% year over year), net income $6.89M, EPS $0.11
- Quarter ended Sep 30, 2022: revenue $65.3M (down 6.8% year over year), net income $3.27M, EPS $0.06
- Quarter ended Jun 30, 2022: revenue $64.4M (down 5.2% year over year), net income $2.57M, EPS $0.05
- Quarter ended Mar 31, 2022: revenue $60.2M (down 4.0% year over year), net income −$6.43M, EPS −$0.11
- Quarter ended Dec 31, 2021 (from the annual report): revenue $68.0M, net income $7.13M, EPS $0.12
- Quarter ended Sep 30, 2021: revenue $70.1M, net income $7.77M, EPS $0.14
VNDA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$109M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$15.8M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow $12.8M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow $32.0M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow $64.2M, share buybacks n/a
VNDA balance sheet
- Jun 30, 2026: cash $55.9M, total assets $412M, total liabilities $192M, shareholders' equity $220M
- Mar 31, 2026: cash $54.0M, total assets $434M, total liabilities $153M, shareholders' equity $281M
- Dec 31, 2025: cash $84.9M, total assets $489M, total liabilities $162M, shareholders' equity $327M
- Sep 30, 2025: cash $70.0M, total assets $601M, total liabilities $135M, shareholders' equity $466M
- Jun 30, 2025: cash $81.0M, total assets $625M, total liabilities $138M, shareholders' equity $486M
- Mar 31, 2025: cash $112M, total assets $632M, total liabilities $121M, shareholders' equity $511M
- Dec 31, 2024: cash $102M, total assets $656M, total liabilities $118M, shareholders' equity $539M
- Sep 30, 2024: cash $100M, total assets $645M, total liabilities $104M, shareholders' equity $541M
What is VNDA's revenue?
VANDA PHARMACEUTICALS INC reported $216M of revenue over its last four quarters, through June 30, 2026.
Is VNDA profitable?
No. VANDA PHARMACEUTICALS INC lost $275M over the last four quarters.
What is VNDA's EPS?
Diluted earnings per share over the last four quarters were −$4.64; −$1.04 in the latest quarter.